ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.

Asma Dilawari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.